Evidence map›Paper›PMID 39124622›Full record

ReviewJournal of clinical medicine2024

Understanding the Role of Sex Hormones in Cardiovascular Kidney Metabolic Syndrome: Toward Personalized Therapeutic Approaches.

Mustafa Guldan, Selen Unlu, Sama Mahmoud Abdel-Rahman, Laşin Ozbek, Abduzhappar Gaipov, Andreea Covic, Maria José Soler, Adrian Covic, Mehmet Kanbay

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mustafa GuldanDepartment of Medicine, Koç University School of Medicine, 34450 Istanbul, Turkey.ORCID 0000-0002-0480-5370
Selen UnluDepartment of Medicine, Koç University School of Medicine, 34450 Istanbul, Turkey.
Sama Mahmoud Abdel-RahmanDepartment of Medicine, Koç University School of Medicine, 34450 Istanbul, Turkey.ORCID 0009-0005-1980-7749
Laşin OzbekDepartment of Medicine, Koç University School of Medicine, 34450 Istanbul, Turkey.ORCID 0000-0002-2828-555X
Abduzhappar GaipovDepartment of Medicine, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.ORCID 0000-0002-9844-8772
Andreea CovicDepartment of Nephrology, Grigore T. Popa University of Medicine, 700115 Iasi, Romania.
Maria José SolerNephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, 08035 Barcelona, Spain.ORCID 0000-0003-3621-0766
Adrian CovicDepartment of Nephrology, Grigore T. Popa University of Medicine, 700115 Iasi, Romania.ORCID 0000-0002-9985-2486
Mehmet KanbayDivision of Nephrology, Department of Medicine, Koç University School of Medicine, 34450 Istanbul, Turkey.ORCID 0000-0002-1297-0675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular kidney metabolic (CKM) syndrome represents a complex interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic comorbidities, posing a significant public health challenge. Gender exerts a critical influence on CKM syndrome, affecting the disease severity and onset through intricate interactions involving sex hormones and key physiological pathways such as the renin-angiotensin system, oxidative stress, inflammation, vascular disease and insulin resistance. It is widely known that beyond the contribution of traditional risk factors, men and women exhibit significant differences in CKM syndrome and its components, with distinct patterns observed in premenopausal women and postmenopausal women compared to men. Despite women generally experiencing a lower incidence of CVD, their outcomes following cardiovascular events are often worse compared to men. The disparities also extend to the treatment approaches for kidney failure, with a higher prevalence of dialysis among men despite women exhibiting higher rates of CKD. The impact of endogenous sex hormones, the correlations between CKM and its components, as well as the long-term effects of treatment modalities using sex hormones, including hormone replacement therapies and gender-affirming therapies, have drawn attention to this topic. Current research on CKM syndrome is hindered by the scarcity of large-scale studies and insufficient integration of gender-specific considerations into treatment strategies. The underlying mechanisms driving the gender disparities in the pathogenesis of CKM syndrome, including the roles of estrogen, progesterone and testosterone derivatives, remain poorly understood, thus limiting their application in personalized therapeutic interventions. This review synthesizes existing knowledge to clarify the intricate relationship between sex hormones, gender disparities, and the progression of CVD within CKM syndrome. By addressing these knowledge gaps, this study aims to guide future research efforts and promote tailored approaches for effectively managing CKD syndrome.

Indexed as

cardiovascular kidney metabolic syndromechronic kidney diseasediabetes mellitusmetabolic syndromesex hormone

Identifiers

PMID39124622
PMCPMC11312746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.